Mayzent

Novartis hit with another serious drug marketing breach, this time for multiple sclerosis therapy Mayzent
Fierce Pharma
Thu, 09/21/23 - 10:36 am
Novartis
UK
PMCPA
pharma marketing
Mayzent
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Fierce Pharma
Tue, 04/21/20 - 11:55 pm
Novartis
Mayzent
MS
multiple sclerosis
Gilenya
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
Tue, 11/19/19 - 02:41 pm
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
Five drugs, including two Novartis therapies, win EMA endorsement
Endpoints
Fri, 11/15/19 - 12:22 pm
EMA
Europe
Novartis
Mayzent
Isturisa
Roche
Polivy
Jazz Pharma
Sunosi
Rigel Pharma
Tavlesse
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
Tue, 08/13/19 - 11:43 am
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Fri, 06/21/19 - 11:33 pm
Novartis
Mayzent
JNJ
Spravato
ICER
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Thu, 05/9/19 - 10:43 am
Novartis
Mayzent
siponimod
multiple sclerosis
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Mon, 05/6/19 - 07:30 pm
Novartis
FDA
Mayzent
siponimod
clinical trials
multiple sclerosis
FDA approves Novartis' Mayzent for MS
BioCentury
Tue, 03/26/19 - 11:02 pm
FDA
Novartis
Mayzent
siponimod
relapsing multiple sclerosis